Recruiting

Testing a new drug combined with standard chemotherapy for advanced blood cancer

Plain-English translation of NCT06207123 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing a new experimental drug called to see if it can work safely alongside (an already-approved leukemia medication) and standard chemotherapy drugs. Researchers want to find the right doses of these medications that are both safe and effective for adults whose leukemia has come back or stopped responding to previous treatment. This combination of treatments is designed to attack the cancer from multiple angles.

Patients with relapsed or treatment-resistant T-cell leukemia have limited options and poor outcomes with current standard treatments alone. This trial is exploring whether adding this new medication to the existing treatment approach might improve how well the treatment works and offer hope to patients who haven't responded to other therapies.

Do you qualify?

You likely qualify if…

you have been diagnosed with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or is not responding to previous treatment
you are 18 years old or older
you have adequate kidney and liver function as measured by blood tests
you have not had major surgery or radiation within the past 2 weeks
you are willing to use effective birth control during the study and for several months after treatment ends (if you could become pregnant or father a child)
you are able and willing to attend study visits and follow the treatment plan

You likely don't qualify if…

you have active leukemia in your central nervous system (brain or spinal cord)
you have a current or chronic hepatitis B or C infection, or untreated HIV infection
you have had major surgery recently or are too ill to tolerate the treatment demands
you cannot commit to the study schedule and follow-up requirements

What participation looks like

You would take the new experimental medication and another medication by mouth every day at home. You would also receive standard chemotherapy drugs during the study cycles, including injections into your spinal canal. In the first cycle (3 weeks), you would have 7 visits to the clinic for blood tests and check-ups; in later cycles, you would have 5 visits per cycle. The study lasts up to 12 cycles (about 9 months), with regular monitoring to watch for side effects and how well the treatment is working.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(2 sites)

United States

University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

University of Rochester Medical Center, Wilmot Cancer Center, Rochester, New York